검색어: hypophysitis (영어 - 덴마크어)

hypophysitis (hypopituitarism)
hypofysitis (hypopituitarisme)

grade 4 hypophysitis
grad 4 hypofysitis

hypopituitarism (including hypophysitis)c, hypothyroidismc
hypopituitarisme (herunder hypofysitis)c, hypotyroidismec

hypophysitis resolved in 7 patients, 2 with sequelae.
hypofysitis gik over hos 7 patienter, 2 med sequelae.

symptomatic grade 2 or 3 hypothyroidism, hyperthyroidism, hypophysitis,
symptomatisk grad 2 eller 3 hypotyroidisme, hypertyroidisme, hypofysitis

adrenal insufficiency, hypopituitarism, hypophysitis, thyroiditis, diabetic ketoacidosis
binyrebarkinsufficiens, hypopituitarisme, hypofysitis, tyroiditis, diabetisk ketoacidose

adrenal insufficiency, hypopituitarism, hypophysitis, hyperthyroidism, thyroiditis, hyperglycaemiab
binyrebarkinsufficiens, hypopituitarisme, hypofysitis, hypertyroidisme, tyroiditis, hyperglykæmib

hypophysitis led to discontinuation of pembrolizumab in 4 (0.1%) patients.
hypofysitis medførte seponering af pembrolizumab hos 4 (0,1%) patienter.

there were no reports of hypophysitis, diabetes mellitus, or diabetic ketoacidosis in these studies.
der var ingen rapporter om hypofysitis, diabetes mellitus eller diabetisk ketoacidose i disse studier.

for symptomatic hypophysitis, nivolumab should be withheld, and hormone replacement should be initiated as needed.
ved symptomatisk hypofysitis bør nivolumabdosering udsættes og hormonsubstitution initieres efter behov.

the median time to onset of hypophysitis was 3.7 months (range 1 day to 11.9 months).
den mediane tid til indtræden af hypofysitis var 3,7 måneder (interval: 1 dag til 11,9 måneder).

for symptomatic grade 2 or 3 hypophysitis, nivolumab or nivolumab in combination with ipilimumab should be withheld, and hormone replacement should be initiated as needed.
ved symptomatisk grad 2 eller 3 hypofysitis bør nivolumab eller nivolumab i kombination med ipilimumab udsættes og hormonsubstitution initieres efter behov.

patients should be monitored for signs and symptoms of hypophysitis (including hypopituitarism and secondary adrenal insufficiency) and other causes excluded.
patienterne skal monitoreres for tegn og symptomer på hypofysitis (inklusive hypofyseinsufficiens (hypopituitarisme) og sekundær binyrebarkinsufficiens), og andre årsager skal udelukkes.

severe endocrinopathies, including hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, diabetes mellitus, and diabetic ketoacidosis have been observed with nivolumab treatment.
svære endokrinopatier, herunder hypotyroidisme, hypertyroidisme, binyrebarkinsufficiens, hypofysitis, diabetes mellitus og diabetisk ketoacidose er observeret med nivolumab-behandling.

severe endocrinopathies, including hypophysitis (including hypopituitarism and secondary adrenal insufficiency), type 1 diabetes mellitus, diabetic ketoacidosis, hypothyroidism, hyperthyroidism and thyroiditis
svære endokrinopatier, inklusive hypofysitis (inklusive hypopituitarisme og sekundær binyrebarkinsufficiens), type 1-diabetes mellitus, diabetisk ketoacidose, hypotyroidisme, hypertyroidisme og tyroiditis

decreased secretion of hormones produced by adrenal glands (glands situated above the kidneys), underactive function (hypopituitarism) or inflammation (hypophysitis) of the pituitary gland situated at the base of the brain, swelling of the thyroid gland, acid in the blood produced from diabetes (diabetic ketoacidosis)
nedsat udskillelse af de hormoner, der dannes i binyrerne (kirtler placeret over nyrerne), nedsat funktion af eller betændelse i hypofysen (sidder nederst i hjernen), hævelse af skjoldbruskkirtlen, syrestoffer i blodet som følge af sukkersyge (diabetisk ketoacidose)